News
CellCentric pockets $220m for blood cancer programme
CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.
News
BioNTech winds down COVID jab manufacturing, shedding staff
BioNTech's plan to shed 22% of its workforce and stop COVID-19 vaccine production has earned it a rebuke from Germany's third-largest labour union.
News
UK's Cytospire draws in $83m for new T-cell engager platform
Cytospire was in the spotlight this morning after announcing an oversubscribed Series A to fund a new form of T-cell engager (TCE) for cancer.
News
'Seismic shift' as obesity overtakes cancer for R&D returns
For the first time in its 16-year history, Deloitte's annual report on pharma R&D returns sees obesity replace cancer as the largest driver.
News
Pfizer, Arvinas join SERD club with Veppanu approval
Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
